Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Acorda Therapeutics Inc Stock Research

ACOR

14.99USD+0.47(+3.24%)Market Closed
Watchlist

Market Summary

USD14.99+0.47
Market Closed
3.24%

ACOR Stock Price

ACOR RSI Chart

ACOR Valuation

Market Cap

18.6M

Price/Earnings (Trailing)

-0.89

Price/Sales (Trailing)

0.16

EV/EBITDA

-0.16

Price/Free Cashflow

-1.64

ACOR Price/Sales (Trailing)

ACOR Profitability

EBT Margin

-25.23%

Return on Equity

-75.65%

Return on Assets

-15.53%

Free Cashflow Yield

-60.95%

ACOR Fundamentals

ACOR Revenue

Revenue (TTM)

116.9M

Revenue Y/Y

-4.43%

Revenue Q/Q

33.32%

ACOR Earnings

Earnings (TTM)

-20.9M

Earnings Y/Y

79.9%

Earnings Q/Q

44.24%

Price Action

52 Week Range

0.2818.20
(Low)(High)

Last 7 days

-4.0%

Last 30 days

29.8%

Last 90 days

15.2%

Trailing 12 Months

5317.4%

ACOR Financial Health

Current Ratio

1.96

Debt/Equity

1.96

Debt/Cashflow

-0.09

ACOR Investor Care

Shares Dilution (1Y)

43.75%

Diluted EPS (TTM)

-5.75

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for ACOR

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-17
COHEN RON
bought
6,500
0.65
10,000
president and ceo
2023-03-16
COHEN RON
bought
6,093
0.6
10,156
president and ceo
2022-09-03
Clem Kerry M
sold (taxes)
-601
0.398
-1,511
chief commercial officer
2022-09-03
Sabella Lauren M
sold (taxes)
-601
0.398
-1,511
chief operating officer
2022-03-17
COHEN RON
sold
-3,894
1.7014
-2,289
president and ceo
2021-09-03
Morales Robert
sold (taxes)
-1,962
4.38
-448
interim pao & pfo
2021-09-03
Sabella Lauren M
sold (taxes)
-6,618
4.38
-1,511
chief commercial officer
2021-09-03
COHEN RON
sold (taxes)
-17,257
4.38
-3,940
president and ceo
2021-03-03
BLANK BURKHARD
acquired
-
-
11,125
cmo and head of r&d
2021-03-03
Sabella Lauren M
acquired
-
-
11,125
chief commercial officer

1–10 of 49

Which funds bought or sold ACOR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-12
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP
sold off
-100
-1,009,720
-
-%
2023-09-12
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP
new
-
716,885
716,885
0.02%
2023-08-21
OSAIC HOLDINGS, INC.
new
-
13.00
13.00
-%
2023-08-21
ADVISOR GROUP HOLDINGS, INC.
sold off
-100
-
-
-%
2023-08-15
WELLS FARGO & COMPANY/MN
new
-
48,657
48,657
-%
2023-08-15
WELLS FARGO & COMPANY/MN
sold off
-100
-43,804
-
-%
2023-08-14
Royal Bank of Canada
new
-
7,000
7,000
-%
2023-08-14
DEUTSCHE BANK AG\
new
-
22,117
22,117
-%
2023-08-14
Royal Bank of Canada
sold off
-100
-
-
-%
2023-08-14
VANGUARD GROUP INC
sold off
-100
-93,630
-
-%

1–10 of 39

Latest Funds Activity

Are funds buying ACOR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ACOR
No. of Funds

Schedule 13G FIlings of Acorda Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 10, 2023
davidson kempner capital management lp
0.13%
31,311
SC 13D/A
Mar 10, 2023
davidson kempner capital management lp
0.21%
51,189
SC 13D/A
Feb 14, 2023
canyon capital advisors llc
0.00%
0
SC 13G/A
Feb 13, 2023
renaissance technologies llc
3.57%
868,892
SC 13G/A
Jan 23, 2023
davidson kempner capital management lp
0.24%
59,129
SC 13D/A
Jun 10, 2022
soros fund management llc
0%
0
SC 13G
Jun 10, 2022
davidson kempner capital management lp
0.28%
68,229
SC 13D
Feb 14, 2022
ubs oconnor llc
0%
0
SC 13G/A
Feb 14, 2022
point72 asset management, l.p.
4.1%
464,276
SC 13G/A
Feb 14, 2022
canyon capital advisors llc
5.79%
649,031
SC 13G/A

Recent SEC filings of Acorda Therapeutics

View All Filings
Date Filed Form Type Document
Aug 09, 2023
10-Q
Quarterly Report
Aug 08, 2023
8-K
Current Report
Jun 27, 2023
8-K
Current Report
Jun 26, 2023
8-K
Current Report

Peers (Alternatives to Acorda Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
143.8B
26.6B
4.22% 19.52%
18.02
5.41
0.75% 21.34%
93.5B
27.4B
-3.50% 20.95%
17.04
3.41
-0.48% 32.56%
39.4B
10.7B
-11.43% -12.52%
32.6
3.69
-53.67% -91.41%
37.2B
10.0B
-3.81% -2.75%
13.96
3.73
-6.23% 29.40%
MID-CAP
11.0B
1.7B
3.79% 9.48%
62.24
6.56
29.01% 1345.90%
4.3B
-
-13.26% 158.53%
-7.29
48.33
54.84% -12.96%
2.8B
-
-11.57% -29.57%
-22.07
37.44
122.90% 54.78%
1.9B
80.2M
2.30% -49.37%
-5.73
23.39
42.17% -39.82%
SMALL-CAP
1.3B
121.2M
-10.65% -29.69%
-4.65
11.03
-70.36% -531.73%
1.0B
15.3M
-19.06% 2.95%
-5.55
65.91
1090.59% -36.57%
682.8M
1.6B
-13.40% -61.01%
-1.16
0.43
23.74% 60.24%
208.9M
-
-19.70% -90.51%
-0.99
1.53
116.83% 16.61%
114.6M
2.1M
-6.34% -64.60%
-1.14
55.76
487.70% -8.66%
104.6M
-
-36.73% -87.68%
-0.53
0.43
113.96% -15.19%
6.2M
-
-2.07% -93.34%
-0.08
3.21
- -129.46%

Acorda Therapeutics News

Defense World
Acorda Therapeutics (NASDAQ:ACOR) Shares Cross Above Two ....
Defense World,
10 days ago
Genetic Engineering & Biotechnology News
StockWatch: Catalent Cuts Revenue, EBITDA Forecasts, Rattling ....
Genetic Engineering & Biotechnology News,
4 months ago
Business Wire
ESTEVE Launches INBRIJA® in Spain.
Business Wire,
6 months ago
Scenari Economici
Investing.com India

Returns for ACOR

Cumulative Returns on ACOR

-23.3%


10-Year Cumulative Returns

-26.2%


7-Year Cumulative Returns

-33.8%


5-Year Cumulative Returns

64.9%


3-Year Cumulative Returns

Risks for ACOR

What is the probability of a big loss on ACOR?

100%


Probability that Acorda Therapeutics stock will be more than 20% underwater in next one year

100%


Probability that Acorda Therapeutics stock will be more than 30% underwater in next one year.

100%


Probability that Acorda Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ACOR drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Acorda Therapeutics was unfortunately bought at previous high price.

Drawdowns

Financials for Acorda Therapeutics

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-1.2%116,914,000118,290,000118,566,000124,063,000122,008,000122,742,000129,071,000130,263,000151,897,000153,730,000152,967,000165,303,000159,935,000176,370,000192,408,000211,064,000306,156,000409,405,000471,433,000590,679,000588,930,000
Costs and Expenses-7.9%136,744,000148,403,000153,906,000171,229,000187,194,000189,702,000208,109,000276,137,000258,725,000254,419,000231,043,000150,500,000420,519,000450,793,000504,040,000586,483,000393,928,000414,753,000432,947,000720,971,000749,678,000
  S&GA Expenses-8.1%93,590,000101,832,000106,256,000108,442,000115,068,000117,369,000124,399,000128,835,000139,147,000145,435,000152,576,000160,923,000169,690,000181,229,000192,846,000188,441,000183,310,000177,378,000172,254,000174,954,000172,124,000
  R&D Expenses0.5%5,521,0005,496,0005,804,0005,968,0006,516,0007,365,00010,420,00013,377,00017,175,00020,056,00023,012,00027,712,00038,056,00051,760,00060,083,00078,118,00084,900,00091,851,000106,383,000114,467,000124,898,000
EBITDA-100.0%-32,552,00027,762,000-12,640,000-30,149,000-33,002,000-45,086,000-110,011,000-68,507,000-60,219,000-35,795,000112,529,000-163,486,000-176,584,000-217,803,000-343,945,000-62,804,00012,367,00053,499,000-113,048,000-141,376,000
EBITDA Margin-100.0%-0.280.23-0.10-0.25-0.27-0.35-0.84-0.45-0.39-0.230.68-1.02-1.00-1.13-1.63-0.210.030.11-0.19-0.24
Interest Expenses1.0%30,508,00030,209,00030,200,00029,839,00029,541,00029,772,00030,035,00030,461,00031,054,00030,833,00030,574,00028,380,00025,120,00023,014,00021,872,00021,573,00022,488,00022,524,00021,597,00021,207,00019,972,000
Earnings Before Taxes29.4%-21,072,000-29,845,000-35,247,000-75,720,000-93,458,000-96,734,000-109,074,000-176,333,000-137,345,000-130,800,000-107,667,00043,354,000-228,976,000-239,398,000-274,248,000-392,576,000-105,001,000-23,176,00020,423,000-149,123,000-179,507,000
EBT Margin100.0%--0.25-0.30-0.61-0.77-0.79-0.85-1.35-0.90-0.85-0.700.26-1.43-1.36-1.43-1.86-0.34-0.060.04-0.25-0.30
Net Income64.1%-20,917,000-58,218,000-65,916,000-105,625,000-118,842,000-95,024,000-103,954,000-166,440,000-132,022,000-126,579,000-99,600,00049,114,000-221,768,000-231,833,000-272,966,000-329,031,000-79,407,000-5,724,00033,682,000-146,977,000-158,261,000
Net Income Margin100.0%--0.49-0.56-0.85-0.97-0.77-0.81-1.28-0.87-0.82-0.650.30-1.39-1.31-1.42-1.56-0.26-0.010.07-0.25-0.27
Free Cashflow100.0%--14,441,000-21,060,000-26,887,000-34,033,000-28,273,000-41,513,000-43,620,000-37,365,000-51,288,000-65,396,000-91,969,000-132,707,000-157,466,000-218,593,000-216,270,000-106,358,000-8,580,000117,465,000197,798,000181,521,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-2.7%3653753963934064244554664915846337107287548008801,1971,2341,3001,3111,251
  Current Assets-4.7%65.0068.0082.0072.0077.0080.0010297.00113190221152158168201314358418528547495
    Cash Equivalents-16.5%25.0030.0038.0021.0023.0032.0046.0036.0046.0011771.0058.0041.0032.0062.00120148197294321243
  Inventory9.9%15.0013.0013.0015.0015.0015.0019.0021.0025.0027.0029.0030.0033.0026.0025.0027.0028.0031.0029.00--
  Net PPE-9.2%2.002.003.003.003.004.004.005.006.006.007.0013914214314313111383.0061.0052.0043.00
  Goodwill-----------------281280282283284
  Current Liabilities-12.5%30.0035.0038.0042.0041.0046.0054.0068.0068.0013313713913871.0086.0092.0094.0097.00140136121
Shareholder's Equity-11.8%68.0077.0094.0076.0088.00128151164190206238314291307311281545567612599607
  Retained Earnings-1.0%-962-953-936-955-941-894-870-849-822-799-766-683-690-673-666-732-468-441-393-403-389
  Additional Paid-In Capital0.0%1,0301,0301,0301,0301,0291,0241,0231,0161,0161,0081,0081,0009839819791,0151,0121,0091,0051,000993
Shares Outstanding2.1%1.001.00-1.001.001.00-1.000.000.00-0.000.000.00-0.000.000.00-0.000.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations20.7%-11.35-14.30-20.92-26.75-33.92-28.10-41.35-43.14-37.03-49.11-61.01-73.88-95.33-89.45-128-129-26.5545.00151224197
  Share Based Compensation-31.8%1.001.001.002.002.003.003.004.006.007.008.009.0010.0013.0014.0017.0018.0019.0021.0024.0025.00
Cashflow From Investing----0.14-0.26-0.11-0.1874.0079.0099.0012259.0011087.0029.00-0.50-71.33-70.77-83.41-176-162-161
Cashflow From Financing--------69.65-69.65-69.74-0.74-1.67-61.54-61.45-61.49-60.55-0.622.0011.0013.0067.0066.00
  Buy Backs---------------0.000.000.001.002.002.002.00

ACOR Income Statement

2023-06-30
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:    
Total net revenues$ 29,675$ 31,051$ 51,933$ 53,585
Costs and expenses:    
Cost of sales3,0658,8006,29914,768
Research and development1,5501,5252,9363,219
Selling, general and administrative21,82530,06744,33957,005
Amortization of intangible assets7,6917,69115,38215,382
Change in fair value of derivative liability (7) (37)
Changes in fair value of acquired contingent consideration(824)(3,110)(1,915)(6,133)
Total operating expenses33,30744,96667,04184,204
Operating loss(3,632)(13,915)(15,108)(30,619)
Other income (expense), net:    
Interest and amortization of debt discount expense(7,773)(7,474)(15,344)(15,036)
Interest income582015121
Other income21,250941,250
Realized loss on foreign currency transactions(1) (1) 
Total other expense, net(7,714)(6,204)(15,100)(13,765)
Loss before taxes(11,346)(20,119)(30,208)(44,384)
Benefit from (provision for) income taxes1,965(26,563)4,003(26,821)
Net loss$ (9,381)$ (46,682)$ (26,205)$ (71,205)
Net loss per share—basic$ (7.55)$ (54.01)$ (21.10)$ (97.33)
Net loss per share—diluted$ (7.55)$ (54.01)$ (21.10)$ (97.33)
Weighted average common shares outstanding used in computing net loss per share-basic1,2428641,242732
Weighted average common shares outstanding used in computing net loss per share-diluted1,2428641,242732
Net Product Revenues    
Revenues:    
Total net revenues$ 25,965$ 27,484$ 44,684$ 46,059
Royalty Revenues    
Revenues:    
Total net revenues3,687$ 3,5677,215$ 7,526
License revenues    
Revenues:    
Total net revenues$ 23 $ 34 

ACOR Balance Sheet

2023-06-30
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 25,270$ 37,536
Restricted cash8286,884
Trade accounts receivable, net of allowances of $875 and $842, as of June 30, 2023 and December 31, 2022, respectively13,39013,866
Prepaid expenses5,4804,312
Inventory, net14,79712,752
Other current assets5,1496,765
Total current assets64,91482,115
Property and equipment, net of accumulated depreciation2,1632,603
Intangible assets, net of accumulated amortization289,700305,087
Right of use asset, net of accumulated amortization4,7655,287
Restricted cash255255
Other non-current assets2,899248
Total assets364,696395,595
Current liabilities:  
Accounts payable3,1759,809
Accrued expenses and other current liabilities21,82223,680
Current portion of lease liabilities1,5671,545
Current portion of acquired contingent consideration3,2742,532
Deferred revenue548384
Total current liabilities30,38637,950
Convertible senior notes176,164167,031
Non-current portion of acquired contingent consideration35,22638,668
Non-current portion of lease liabilities3,7644,341
Deferred tax liability39,55644,202
Other non-current liabilities11,7329,781
Stockholders’ equity:  
Preferred stock, $0.001 par value per share. Authorized 1,000,000 shares at June 31, 2023 and December 31, 2022; no shares issued as of June 30, 2023 and December 31, 2022, respectively
Common stock, $0.001 par value per share. Authorized 3,083,333 shares at June 30, 2023 and December 31, 2022; issued 1,242,376 shares,including those held in treasury, as of June 30, 2023 and December 31, 2022, respectively124
Treasury stock at cost (278 shares at June 30, 2023 and December 31, 2022)(638)(638)
Additional paid-in capital1,030,1031,029,881
Accumulated deficit(962,478)(936,273)
Accumulated other comprehensive income880628
Total stockholders’ equity67,86893,622
Total liabilities and stockholders’ equity$ 364,696$ 395,595
Ronald Cohen
130
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.